Login to Your Account

Clinic Roundup

Thursday, September 13, 2012

• e-Therapeutics plc, of Oxford, UK, said it started a second Phase I trial testing cancer drug ETS2101, a drug designed to promote apoptosis. The dose-escalating study is expected to enroll up to 45 patients with a variety of solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription